Tavernier Tschanz advised JSR Life Sciences in the expansion of its European gene-to-GMP biologics manufacturing facilities for Selexis and KBI Biopharma

JSR Life Sciences, LLC is increasing its European footprint with a newly expanded, state-of-the-art facility that will co-locate primary European operations for its affiliated companies KBI Biopharma and Selexis SA. The two companies combined will occupy 8,700 square meters in the Stellar 32 campus within Geneva’s ZIPLO (Industrial Zone Plan-les-Ouates). KBI Biopharma’s expanded facility will enable the company to offer clinical cGMP biologics bulk drug substance manufacturing for European clients. Selexis’ new workspaces will allow the company to meet the increasing demand for its highly specialized mammalian cell line development technologies and services. Together, the companies anticipate creating more than 250 new highly technical jobs in the new facilities.

Tavernier Tschanz advised JSR Life Sciences, and its affiliated entities KBI Biopharma and Selexis SA, in this transaction.

The team was led by Jacques Bonvin and included Nicolas de Weck.